Conference 2021 Program

Opening Ceremonies

Time (EST)TopicSpeaker
7:00 – 7:10 amOpening Ceremony – Introduction and Welcome from BSIDr. Eleanor Fish,
Univ. of Toronto, Canada

Scientific Session 1 : Infectious Diseases 1

Time (EST)TopicSpeaker
7:15–7:50 amKeynote 1– Developing new treatments for COVID-19: Focus on inhaled interferon-βDr. Tom Wilkinson,
University of Southampton, Southampton, UK
7:55–8:10 amMolecular interplay between SARS-CoV-2 and human proteins for viral activation and entry, potential drugs and scope for new therapeuticsDr. Naveen Vankadari,
Monash University, Australia
8:15–8:30 amUncommon consequences of SARS-CoV-2 on the nervous systemNatalie Perez-Mendez,
Poznan Medical School, Poland
8:35–8:50 amEpidemiological and spatial analysis of COVID-19 cases in Native Amazonian communities from PeruCecilia Isabel Pajuelo Reyes,
Uni. Mendoza, Peru
8:55–9:10 amScreening of FDA approved drugs as modulators of Multidrug Resistance Protein 2 (MRP2/ABCC2) protein expression in MRP2-overexpressing cellsVivian Osei Poku,
South Dakota State U., USA
9:15–9:30 am
Students Against COVID: Building a hashtag up to a global communityChristos Tsagkaris
University of Crete, Greece
9:30–9:45 amBreak

Scientific Session 2 : Infectious Diseases 2

Time (EST)TopicSpeaker
9:45–10:20 amKeynote 2– Systems Serology to Define Correlates of Immunity to SARS-CoV-2Dr. Galit Alter
Harvard University, USA
10:25–10:40 amTranscriptional silencing by TsrA in the evolution of pathogenic Vibrio cholerae biotypesDr. Florencia Caro,
Harvard Medical School, USA
10:45-11:00 amAn Adenovirus-Vectored Vaccine Protects from Intestinal Schistosomiasis in a Pre-Clinical ModelDilhan Perera,
McGill University, Canada
11:05–11:20 amElucidating mechanisms by which mutations in Env contribute to broad, multi-class HIV-1 drug resistancePhuong Pham,
Oxford University, UK
11:25–11:40 amConcomitant infection of Leishmania Donovani and Plasmodium Berghei reduces disease severity in BALB/c miceRebeccah Ayako,
Kenyatta University, Kenya
11:45-12:00 pmPotential effects of treatment with Itolizumab for decreasing plasma IL-6 levels in severely ill patients with COVID-19Vityala Yethindra,
IUK, Kyrgyzstan
12:00–12:15 am
Sustainable Development Goals 2030 on stigmatization of HIV in Nigeria: research studies, policies and programsAbdullahi Aborode,
University of Ilorin, Nigeria
12:15–12:30 am
COVID19 pandemic and the vulnerable groups: the Brazilian experienceFernanda de Castro Nakamura,
São Paulo State University, Brazil

Scientific Session 3: Chronic Diseases and Biotechnology

Time (EST)TopicSpeaker
7:00–7:35 amKeynote 3– The alliance for accelerating excellence in science in AfricaDr. Tom Kariuki
African Academy of Sciences
7:40–7:55 amSerelaxin-nanoparticles abrogates inflammation and remodeling associated with chronic allergic airways disease through specific myeloid cell subsetsDr. Amlan Chakraborty,
Monash University, Australia
8:00–8:15 amAltered Levels of immune checkpoint molecules in colon biopsies and sera from microscopic colitis and ulcerative colitis patients compared to controlsAlexandra Lushnikova,
Örebro University, Sweden
8:20–8:35 amSynthesis of defined homogeneous site-specific ubiquitin conjugates by a chemo-enzymatic sortase mediated ligation strategyDr. Avinash Singh,
University of Wroclaw/ NII, Poland/ India
8:40–8:55 amMaternal factors orchestrate multigenerational transfer of immune traitsDr. Deepshika Ramanan,
Harvard Medical School, USA
8:55–9:10 amEffects of Omega-3 fatty acids and pioglitazone combination on insulin resistance through fibroblast growth factor 21 in type 2 diabetes mellitusDr. Salma Eraky
Mansouria University, Egypt
9:15–9:30 amIn-Silico Prediction of T- cell epitopes in VacA: First Step towards the Design of a Helicobacter Pylori VaccineAina Abisola Temiloluwa,
Adeleke University, Nigeria
9:35–9:50 am
Innovative approaches to oncology training and care amid COVID-19 pandemic in Sub-Saharan AfricaNicholas Muema
International Cancer Institute and Moi University, Kenya
9:50–10:00 amBreak

Scientific Session 4: Cancer

Time (EST)TopicSpeaker
10:00-10:35 amKeynote 4– How to inhibit the undruggable MYC oncoprotein in cancerDr. Linda Penn,
University Health Network, Canada
10:40-10:55 amDevelopment of novel auristatin F-containing immunoconjugates for the treatment of triple-negative breast cancerNeelakshi Mungra,
University of Cape Town, South Africa
11:00–11:15 amLncRNA LINC00511 from newly diagnosed Egyptian breast cancer patients: A tale of a promising diagnostic molecular biomarkerMarwa Mahmoud,
Ain Shams University, Egypt
11:20 –11:35 amTIMD4 and CCR2 mark resident tissue macrophage subsets with conserved lifecycles across organsAnthony Wong,
University of Toronto, Canada
11:40–11:55 amF-box only protein FBXO31 functions as a tumor suppressor by inactivating oncogenes associated with ovarian cancer malignancySebhanul Islam,
Nat. Centre for Cell Science, India
12:00–12:15 pmAnalysis of genetic polymorphisms of PD-1 gene in breast cancer patientsSarah Moretto,
State University Londrina, Brazil
12:20-12:35 pmArchitecture of the tumor microenvironment predicts response to cancer immunotherapyDr. Christian Schurech,
University Hospital Tubeingen, Germany
12:40-12:55 pmTumor-derived exosomes and immune dysfunction in the tumor microenvironmentPriya Makhijani,
University of Toronto, Canada
1:00–1:15 am
The art of prevention and advocacy: A virtual art exhibition for the European Week Against Cancer amid the pandemicYakup Gozderesi
Marmara University, Turkey
1:15–1:30 am
Health services management research priorities in primary health care for underserved areas of Eastern São Paulo, BrazilAmanda Marcinowska
McGill University, Canada

Click to view